BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24403470)

  • 1. Initial experience with oropharynx-targeted radiation therapy for metastatic squamous cell carcinoma of unknown primary of the head and neck.
    Mourad WF; Hu KS; Shasha D; Concert C; Ishihara D; Lin W; Shourbaji RA; Ryniak M; Gamez ME; Lukens JN; Li Z; Culliney BE; Khorsandi AS; Tran T; Jacobson A; Manolidis S; Schantz S; Urken M; Persky MS; Harrison LB
    Anticancer Res; 2014 Jan; 34(1):243-8. PubMed ID: 24403470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.
    Villeneuve H; Després P; Fortin B; Filion E; Donath D; Soulières D; Guertin L; Ayad T; Christopoulos A; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1866-71. PubMed ID: 21497452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unknown primary head and neck cancer treated with intensity-modulated radiation therapy: to what extent the volume should be irradiated.
    Lu H; Yao M; Tan H
    Oral Oncol; 2009 Jun; 45(6):474-9. PubMed ID: 18804408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure.
    Frank SJ; Rosenthal DI; Petsuksiri J; Ang KK; Morrison WH; Weber RS; Glisson BS; Chao KS; Schwartz DL; Chronowski GM; El-Naggar AK; Garden AS
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1005-10. PubMed ID: 20207504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distant metastases in head-and-neck squamous cell carcinoma treated with intensity-modulated radiotherapy.
    Yao M; Lu M; Savvides PS; Rezaee R; Zender CA; Lavertu P; Buatti JM; Machtay M
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):684-9. PubMed ID: 22169673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy.
    Mourad WF; Hu KS; Shasha D; Concert C; Ishihara D; Lin W; Gamez ME; Lukens JN; Shourbaji RA; Ryniak M; Li Z; Culliney BE; Khorsandi AS; Tran T; Jacobson A; Manolidis S; Schantz S; Urken M; Persky MS; Harrison LB
    Anticancer Res; 2013 Dec; 33(12):5511-6. PubMed ID: 24324090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck.
    Sher DJ; Balboni TA; Haddad RI; Norris CM; Posner MR; Wirth LJ; Goguen LA; Annino D; Tishler RB
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1405-11. PubMed ID: 21177045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
    McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
    Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
    Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
    Sher DJ; Haddad RI; Norris CM; Posner MR; Wirth LJ; Goguen LA; Annino D; Balboni T; Allen A; Tishler RB
    Cancer; 2010 Oct; 116(20):4761-8. PubMed ID: 20572036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head and neck squamous cell carcinoma from an unknown primary site.
    Wallace A; Richards GM; Harari PM; Kirwan JM; Morris CG; Katakam H; Mendenhall WM
    Am J Otolaryngol; 2011; 32(4):286-90. PubMed ID: 20719404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with head-and-neck cancer of unknown primary origin treated with intensity-modulated radiotherapy.
    Shoushtari A; Saylor D; Kerr KL; Sheng K; Thomas C; Jameson M; Reibel J; Shonka D; Levine P; Read P
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e83-91. PubMed ID: 21377283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy.
    Kamal M; Mohamed ASR; Fuller CD; Sturgis EM; Johnson FM; Morrison WH; Gunn GB; Hutcheson KA; Phan J; Volpe S; Ng SP; Ferrarotto R; Frank SJ; Skinner HD; Rosenthal DI; Garden AS
    Cancer; 2018 Apr; 124(7):1415-1427. PubMed ID: 29338089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.
    Daly ME; Lieskovsky Y; Pawlicki T; Yau J; Pinto H; Kaplan M; Fee WE; Koong A; Goffinet DR; Xing L; Le QT
    Head Neck; 2007 Mar; 29(3):211-20. PubMed ID: 17111429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?
    Chen AM; Farwell DG; Lau DH; Li BQ; Luu Q; Donald PJ
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):346-52. PubMed ID: 20933340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: a prospective phase II study.
    Lindholm P; Valavaara R; Aitasalo K; Kulmala J; Laine J; Elomaa L; Sillanmäki L; Minn H; Grénman R
    Radiother Oncol; 2006 Feb; 78(2):146-51. PubMed ID: 16307813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
    Koiwai K; Shikama N; Sasaki S; Shinoda A; Kadoya M
    Jpn J Clin Oncol; 2009 Jul; 39(7):413-7. PubMed ID: 19383615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.